FibroGen, Inc. (FGEN)
NASDAQ: FGEN · Real-Time Price · USD
0.350
0.00 (0.00%)
At close: Nov 20, 2024, 4:00 PM
0.336
-0.014 (-4.00%)
Pre-market: Nov 21, 2024, 4:02 AM EST
FibroGen Employees
FibroGen had 486 employees as of December 31, 2023. The number of employees decreased by 106 or -17.91% compared to the previous year.
Employees
486
Change (1Y)
-106
Growth (1Y)
-17.91%
Revenue / Employee
$370,401
Profits / Employee
-$250,603
Market Cap
35.27M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Co-Diagnostics | 155 |
Barinthus Biotherapeutics | 130 |
Adagio Medical Holdings | 85 |
Elevation Oncology | 29 |
Citius Pharmaceuticals | 22 |
Iterum Therapeutics | 14 |
Dyadic International | 7 |
OS Therapies | 4 |
FGEN News
- 8 days ago - FibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call Transcript - Seeking Alpha
- 8 days ago - FibroGen Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 16 days ago - FibroGen to Report Third Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program - Benzinga
- 4 months ago - FibroGen to Report Second Quarter 2024 Financial Results - GlobeNewsWire
- 5 months ago - FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward - Seeking Alpha
- 6 months ago - FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials - GlobeNewsWire